Open AccessA Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus
Author(s) -
AnneMarie Nardolillo,
Michael P. Kane,
Robert S. Busch,
Jay Watsky,
Robert A. Hamilton
Publication year - 2014
Publication title -
clinical medicine insights endocrinology and diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 15
ISSN - 1179-5514
DOI - 10.4137/cmed.s18182
Subject(s) - canagliflozin , medicine , tolerability , adverse effect , type 2 diabetes mellitus , regimen , type 2 diabetes , diabetes mellitus , endocrinology
To assess the real-world efficacy and safety of the first sodium-glucose cotransporter-2 inhibitor, canagliflozin, in the treatment of patients with type 2 diabetes mellitus (T2DM).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom